Regulus Therapeutics

Acquired

Pioneering microRNA therapeutics for serious diseases

Carlsbad, United States · Founded 2007 · $120.0M raised

Employees
11–50
Founded
2007
Business Model
B2B
Total Funding
$120.0M
Last Round
$20.0M Series A
Rounds
2
Acquired by
Novartis AG

About

Regulus Therapeutics is a biopharmaceutical company founded in 2007 as a joint venture between Alnylam Pharmaceuticals and Ionis Pharmaceuticals. The company pioneered the development of oligonucleotide therapeutics that inhibit dysregulated microRNA targets. Its lead program, farabursen (RGLS8429), targeted ADPKD, the most common genetic cause of renal failure. In April 2025, Novartis agreed to acquire Regulus for up to $14 per share, valuing the deal at approximately $1.7 billion.

Summary

Regulus Therapeutics is a Biotech company based in Carlsbad, United States, founded in 2007. It has raised $120.0M in total across 2 rounds.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries A
$20.0M

Sign up to see all 4 rounds

Series A through Private Equity — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Regulus Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/regulus-therapeutics"><img src="https://indexed.vc/api/badge/company/regulus-therapeutics" alt="Regulus Therapeutics on Indexed.vc" width="260" height="76" /></a>